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Materials and Methods 
Embryo electroporation 
Fertilized eggs from white leghorn chickens were obtained from McIntyre Poultry & 
Fertile Eggs (Lakeside, California). Chicken embryos were electroporated ex ovo using 
previously described techniques (14). Briefly, embryos were dissected from the eggs 
using a filter paper ring and submersed in Ringer’s buffer (15). Morpholinos or 
expression constructs were subsequently micro-injected in the space between the epiblast 
and vitelline membrane. Embryos were electroporated with platinum electrodes (five 
50ms pulses of 5.1V, with an interval of 100ms between pulses). Following 
electroporation, embryos were cultured at 37oC in sterile petri dishes containing fresh 
albumen until the desired stages. Embryo survival was >90%.  
 
Embryo dissociation and cell sorting 
After electroporation with 2ug/ul of the NC1:eGFP (cranial neural crest) or 
NC2:eGFP (trunk neural crest) enhancers, embryos were incubated at 37oC until HH9+ 
and HH14 and screened for robust expression of GFP. Embryos with weak GFP 
expression or at incorrect stages of development were discarded. Dissected heads (HH9+) 
and trunks (HH14) were washed with dPBS and dissociated with Accumax (Accutase 
SCR006) cell dissociation solution. Reaction was stopped by addition of 10x the volume 
of Hanks solution supplemented with 0.5% BSA. Cells were subsequently washed, 
passed through a 40-µm cell strainer (BD Biosciences) and resuspended in Hanks 0.5% 
BSA. Efficiency of dissociation and cell viability was verified with trypan blue staining 
in a hemocytometer using an inverted tissue culture microscope. GFP+ cells were then 
sorted using a BD FACSARIA Cell Sorter (BD Biosciences) with 7-AAD exclusion to 
eliminate dead and damaged cells.  
 
Library building and sequencing 
Library building and sequencing was performed as previously described (10). Sorted cells 
were pelleted, washed with PBS and RNA was extracted with RNAqueous®-Micro Kit 
(Ambion AM1931). Quality of the RNA was assayed in an Agilent 2100 Bioanalyzer. All 
samples had RIN > 8. RNA was subsequently amplified with the Ovation RNA-Seq 
System V2 (NuGEN). The sequencing libraries were built according to the Illumina 
Standard Protocols. SR50 sequencing was performed in a HiSeq2000 Illumina machine. 
Sequence reads were aligned to the Gallus gallus genome with TopHat (16). Cufflinks 
and Cuffdiff (17) were used to calculate gene expression levels and identifying 
differentially expressed transcripts. Two cranial (stage HH9+, NC1:eGFP) and two trunk 
(stage HH14, NC2:eGFP) samples were processed together with Cuffdiff as replicates. A 
gene was considered to be expressed as part of the dataset if three conditions were met: 
(1) the RPKM values (Reads Per Kilobase of exon per Million fragments mapped) for 
that gene were above 5 RPKM in the cranial neural crest; (2) difference in expression 
levels was significant according to statistical analysis at FDR of 0.05 (3) the gene had at 
least 2-fold upregulation in the cranial neural crest. The table with expression levels of 
the genes enriched in the cranial neural crest (Database S1) contains values for samples 
that were processed as replicates in Cufflinks/Cuffdiff. Two genes that were previously 
identified as cranial-specific (Ets1 (18) and Brn3c) failed statistical analysis due to 
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improper genomic annotation; they were included in the in situ hybridization screen and 
subsequent perturbation analysis. 
 
Cloning of cranial genes and in situ hybridization  
Cranial genes identified in the transcriptome analysis were cloned using the TOPO TA 
Cloning Kit Dual Promoter (Invitrogen). cDNA was synthesized with SuperScript® III 
Reverse Transcriptase (Invitrogen), from RNA obtained from dissected cranial neural 
folds obtained from HH8-HH10 chicken embryos. Whole mount in situ hybridization was 
performed as described (19) with modifications including more extensive washes and a 
CHAPS-based hybridization buffer. Double fluorescent in situ hybridization was 
performed using the Tyramide TSA system from Perking Elmer (TSA Plus Cyanine 5 & 
Fluorescein, NEL754001KT), as previously described (20). 
 
Fate-mapping 
The fate map of neural crest progenitors was generated at stages HH8- (3 somites) by 
injection of a single spot of CellTracker CM-DiI on the dorsal surface of the neural plate 
border of individual embryos (21). The embryos were incubated overnight, until they 
reached stage HH 12, when the embryos were fixed and analyzed for the position of the 
labeled cells. The fate map was compiled by marking the coordinates of each individual 
injection spot onto the image of a representative embryo, and color-coding the spots 
according to their fate at stages HH12 (cranial or vagal/trunk neural crest). To compare 
the fate map with the expression of the cranial-specific regulators, we generated a spatial 
average of the Dmbx1 expression domain. We registered the expression pattern of this 
gene from several HH8- embryos and created an overlap of expression domains onto the 
fate map by using a coordinate grid (Fig. 2D). 
 
Perturbation experiments 
In all perturbation experiments, we employed bilateral injections, where the two sides of 
the embryos were transfected with different reagents (11). The left side (control) was 
injected with biotin-labeled control morpholinos or control expression vectors. The right 
side (experimental) was injected with FITC-labelled targeted morpholinos or expression 
vectors. All embryos were screened prior to further analysis; embryos with weak or 
incomplete electroporation, or with morphological abnormalities were discarded. 
Visualization of biotin-labelled control morpholino was performed by incubating 
morphants with 1ng/ul Streptavidin conjugated to Alexa Fluor 647 (Molecular Probes, 
S32357) in PBS Triton (0.3%) for 2 hours, followed by 3 washes of 5 minutes in PBST. 
The following morpholinos were used: Control 
(ATGGCCTCGGAGCTGGAGAGCCTCA) Dmbx1 
(CGTTCACCCCATAGTGCTGCATGGC), Lhx5 
(AGCCCGCACAATGCACCATCATCAC), Sox8 
(TCCTCGGTCATGTTGAGCATTTGG), Tfap2b 
(CAACCAGTTTCCAGAGCATGATGGC) and Ets1 
(GCTTCAGGTCCACCGCCGCCTTCAT). Efficiency of morpholinos was tested by 
fusing the UTRs and the coding sequence of the first 10 amino acids of target genes to 
GFP; electroporation of these constructs with the targeted morpholinos resulted in 
absence of GFP expression (Fig. S2). The Brn3c dominant negative construct was 
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designed according to a previously published expression vector used for Brn2 loss of -
function (22). Effects on downstream genes where scored by comparison between 
targeted (right) and control (left) neural folds of the same embryo; we surveyed gene 
expression of putative downstream targets by in situ hybridization and qPCR. In the 
qPCR analysis, all possible interactions between the 5 factors and Ets1 where surveyed. 
Target for the in situ hybridization analysis were chosen based on onset of gene 
expression shown on Fig. 2E. The sample size for each knockdown experiment was 
determined according to what is deemed appropriate according to the standards of the 
field. No randomization or blinding was performed in the described assays.  
 
Quantitative analysis of gene expression  
For qPCR analysis following knockdown of cranial specific transcription factors, 
embryos were electroporated bilaterally with morpholinos or dominant negative 
constructs (described above), and the expression profile of the targeted neural fold was 
compared to the control side (Fig. 3I). The two neural folds of morphant embryos were 
microdissected at stages HH8-9 and lysed for cDNA synthesis. Samples were prepared 
for RT-qPCR analysis using the TaqMan Cells-to-CT Kit from Ambion, following the 
manufacture’s instructions. Real-time qPCR analysis was performed on an ABI PRISM 
Applied BioSystems 7000 Sequence Detection System using Power SYBR® Green 
Master Mix (Thermo Fisher Scientific). We designed primers for Brn3c, Lhx5, Dmbx1, 
Sox8, Tfap2b, Ets1 and Hprt1 with the Primer3Plus program 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi); real-time PCR 
efficiencies were determined for all sets of designed primers. Expression levels of target 
gene were normalized to the expression of Hprt1, and relative changes in mRNA 
expression between control and loss of function neural folds were determined through the  
2 -ΔΔCt method. Abundance of each cranial specific gene in a targeted neural fold is 
presented relative to the expression levels of the same gene in the control neural fold of 
the same embryo (Fig. 3I). Significant changes in expression levels were determined by 
unpaired Student’s t-test (P < 0.05). 
 
Chromatin immunoprecipitation (ChIP) 
To identify direct interactions between cranial specific transcription factors and 
downstream targets we employed biotin-ChIP (23). Brn3c, Lhx5, Dmbx1, Sox8, Tfap2b 
were fused with an AVI tag and cloned in pCI:H2B-RFP. Embryos were electroporated at 
gastrula stage (HH5) with each of these constructs and a vector driving nuclear 
expression of the E. coli enzyme BirA (pCI:NLS-BirA-Cer), and incubated until stage 
HH8-9. For each experiment, 20 embryos were dissected in Ringer’s solution and 
chromatin prepared from dorsal neural folds was immunoprecipitated as described (23, 
24) using the MyOne™ Streptavidin T1 Dynabeads. Mock controls were transfected with 
pCI:NLS-BirA-Cer only. Enrichment for a specific DNA sequence was calculated using 
the comparative CT method. Since the cis-regulatory apparatus the target genes have not 
all been characterized, we designed primers to target the promotor sequences of these 
genes with the rationale that active transcription factor-bound enhancers loop at the 
chromatin level to interact with their respective promoters; thus, crosslinked pulldowns 
will carry the relevant enhancer and promoter DNA sequences (24). For additional 
controls we employed primers targeting intergenic negative control regions (NCR). All 
 
 
5 
 
primers were designed with the Primer3Plus program. In Fig. 3K the results are presented 
as fold enrichment of control ChIP experiment done with IGG Dynabeads; for each 
experiment the same chromatin was split between Streptavidin T1 Dynabeads and the 
control IGG Dynabeads. The results on Fig. S4 are presented as percent of total input 
used in each immunoprecipitation. 
 
Enhancer reprogramming experiments 
For targeted expression of cranial factors in the trunk neural crest, the coding sequences 
of Brn3c, Lhx5, Dmbx1 were cloned in pCI:H2B-RFP(8). M. Barembaum generously 
provided the Sox8 and Tfap2b expression constructs, which were cloned in the same 
vector. The Ets1 expression vector was available from previous studies (8). In ovo 
electroporation was performed according to the guidelines described by Nakamura and 
Funahashi (25). In the reprogramming experiments, separate vectors encoding each 
transcription factor were co-electroporated. The trunk neural tubes of HH10-11 embryos 
were injected with combinations of expression vectors and electroporated with platinum 
electrodes (five 50ms pulses of 20.5V, with an interval of 100ms between pulses). After 
electroporation, embryos were incubated until stage HH14 and analyzed for ectopic 
activity of cranial enhancer Sox10E2 in the trunk neural crest. Other enhancers tested in 
these experiments were Sox10E1 (8), NC2 (9) and Ets1ECR3 (26). Expression levels of 
cranial genes in the reprogrammed trunk neural crest were assayed by qPCR. As targets, 
we tested genes that are involved in chondrocytic differentiation (Runx2 and Alx1) and 
are enriched in the cranial neural crest (10). The expression levels of reprogrammed cells 
were compared to wild type cranial neural crest (HH10, obtained with the cranial 
Sox10E2 enhancer) and wild type trunk neural crest (HH14, obtained with the trunk 
Sox10E1 enhancer). Pure populations of wild type and reprogrammed neural crest were 
obtained through FACS; cDNA was synthesized with the Power SYBR® Green Cells-to-
CT™ Kit (Ambion 4402953). The bar graphs on Fig. 4F-G represent the average 
normalized levels of Alx1, Runx2, Dbx2 and Hes6 gene expression obtained from three 
biological replicates of the experiment (three distinct FACS sorting sessions). 
 
Enhancer reprogramming experiments 
To test the chondrocytic potential of wild type and reprogrammed trunk neural crest, 
we employed Roslin Green GFP Eggs purchased from Clemson University. Mock 
transfected or reprogrammed trunk neural folds were microdissected from HH11 GFP+ 
donor embryos and grafted into the heads of HH9 wild type hosts (Fig. S7). The chimeras 
were incubated until embryonic day (E) 7, by which time endogenous cartilage cells have 
differentiated, and fixed for histological analysis (see below). We tested the chondrocytic 
potential of mock transfected trunk neural crest, which was electroporated with pCI:H2B-
RFP (n=0/5), and reprogrammed trunk neural crest, which had been transfected with 
expression vectors driving expression of Sox8, Tfap2b and Ets1 (n=4/7). 
 
Sectioning and immunohistochemistry 
For histological analysis, grafted embryos were washed in 5% and 15% sucrose and 
incubated in 17% gelatin for 3 hours at 37°C. Embedded embryos were frozen with liquid 
nitrogen and sectioned at 10-15 µm with a Micron cryostat. For immunostaining we used 
the protocol previously described (21). Slides were de-gelatinized, washed in TBS with 
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0.3% Triton supplemented with 0.1% DMSO and blocked for 2 hours in the same 
solution supplemented with 10% donkey serum. The following antibodies were used: 
anti-GFP antibody produced in rabbit (1:300, Thermo A6455), anti-Collagen type 
IX produced in mouse (1:1, DSHB 2C2) anti-Collagen type II produced in mouse (1:1, 
DSHB II-II6B3). Secondary antibodies used included donkey anti-rabbit IGG, or donkey 
anti-mouse IGM, conjugated with Alexa Fluor 488/555/594/647 (1:2000, Molecular 
probes). For imaging, slides were stained with DAPI and mounted with PermaFluor 
Mounting Medium (Thermo 434990). 
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Fig. S1 
 
 
 
Figure S1. In situ hybridization screen of genes enriched in the cranial neural crest. 
Analysis of expression patterns confirms enrichment of cranial-specific transcriptional 
regulators in the cranial neural crest. These included genes expressed by the whole 
cranial neural crest population (A-F), as well as transcripts present in subsets of cells (G-
L). All pictures show dorsal views of the cephalic regions of chicken embryos after 
chromogenic in situ hybridization. 
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Fig. S2 
 
 
 
Figure S2. Validation of morpholino knockdown efficiency. (A) Diagram of 
expression constructs for testing morpholino efficiency with in vivo translation blocking 
assays.  The UTR and 10 first amino acids of each target genes, which contain the 
morpholino target site, were fused to eGFP. This cassette was cloned downstream of a 
pCaggs constitutive promoter. (B) Bilateral electroporation of control (blue) and targeted 
(green) morpholinos in different sides of the embryo. Both sides were also co-transfected 
with the corresponding expression constructs. (C) Whole-mount dorsal view of embryo 
after Lhx5 morpholino (Mo) and control morpholino (CoMo) were transfected to the 
right and left side of each embryo, respectively. (D) Dorsal view of the embryo pictured 
in (C), showing loss of GFP expression caused by the LhxMO on the right side of the 
embryo (n=8/8). (E-J) Validation of Dmbx1 (n=8/8), Sox9 (n=9/9) and Tfap2b (n=8/8) 
morpholinos. AA: aminoacids. 
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Fig. S3 
 
 
 
Figure S3. Supporting data for loss of function analysis. (A) Brn3c dominant negative 
construct. The Brn3c DNA binding domain (DBD) was fused with to an Engrailed 
repressor domain (EnR), and cloned downstream of a pCaggs constitutive promoter. An 
eGFP reporter linked to the fusion protein with a 2a self-cleaving peptide was added to 
the vector to monitor transfection efficiency. (B) Diagram of bilateral electroporation of 
stage HH4 embryos. (C) Whole-mount dorsal view of embryo after the dominant 
negative (Brn3DN) and a control construct (pCaggs-Cerulean) were transfected to the 
right and left side of each embryo, respectively. (D) The same embryos as (C), after in 
situ hybridization for Dmbx1, with downward blue arrows indicating disruption of gene 
expression on the experimental side (n=10/12). (E) Table summarizing loss-of-function 
experiments, including the number embryos displaying mild (partial loss), strong 
(complete loss) or no effect on putative downstream targets after knockdown of each 
regulator. (F) Gene regulatory interactions revealed by loss of function and qPCR 
analysis. The diagram is based on the data presented on Figure 3I; interactions likely to 
be indirect were omitted.  
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Fig. S4 
 
 
 
 
Figure S4. Chromatin immunoprecipitation (biotin-ChIP) analysis reveals 
transcription factor - promoter interactions in the cranial specific neural crest 
circuit. (A) Diagram showing the transcription factor (TF) promoter interactions tested 
via biotin ChIP. (B-F) ChIP assay performed in dissected dorsal neural folds of stage 
HH9 embryos co-electroporated with expression constructs encoding Avi-tagged TFs and 
the E. coli BirA enzyme. IP of the transcription factors protein with Streptavidin 
Dynabeads, followed by site specific qPCR with primer pairs designed to amplify the 
promoter region of the putative downstream target revealed significant enrichment of the 
target region in the TF pull-down when compared to IGG controls. No enrichment was 
observed for negative control regions (NCR) chosen in intergenic regions, or when the 
experiment was conducted on embryos transfected with BirA only. Enrichment of 
amplicons is expressed as a percent of the total input chromatin used in the IP assay. 
Error bars represent SD.  
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Fig. S5 
 
 
 
Figure S5. Ets1 is required for expression of Alx1 in the late migratory neural crest. 
(A) Diagram of bilateral electroporation of stage HH7 embryos. (B) Whole-mount dorsal 
view of a HH12 embryo after the Ets1 morpholino (Ets1Mo) and control morpholino 
(CoMo) were transfected to the right and left side of each embryo, respectively. (C) 
Transverse section through the midbrain region of the embryo depicted in (B). The right 
side of the embryo, which was electroporated with the Ets1 morpholino, displays loss of 
Alx1 expression (red) in the late migratory neural crest population (n=7/8), as assayed by 
immunohistochemistry with an anti-Alx1 antibody.  
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Fig. S6 
 
 
 
 
Figure S6. Effects of trunk neural crest reprogramming on trunk- and cranial-
specific enhancers. Reprogramming with cranial-specific regulators impacts activity of 
neural crest trunk- and cranial-specific enhancers. (A) The Sox10E1 enhancer is active in 
trunk neural crest populations in wild type (wt) conditions. (B) Reprogramming of the 
trunk neural crest with cranial factors results in loss of Sox10E1 activity. (C and D) The 
trunk FoxD3 enhancer NC2 is also repressed in reprogrammed trunk neural crest cells. 
(E-H) Cranial-specific enhancers Sox10E2 and Ets1ECR3 are ectopically activated in 
trunk neural crest cells following reprogramming. wt: wild type. rep: Reprogrammed.  
 
 
 
 
13 
 
Fig. S7 
  
 
 
Figure S7. Testing neural crest potential with chimeric embryos. (A) Diagram of 
neural crest grafts utilizing GFP+ transgenic embryos. Trunk neural folds were dissected 
from HH11 GFP+ embryos donor embryos from regions posterior to the 10th somite 
(S10). The cells were transplanted to the cranial regions of HH9 wild type embryos. Each 
graft was placed adjacent to the hindbrain. (B and C) Control embryos photographed 
after grafting at stages HH14 and HH32, showing GFP+ neural crest cells invading the 
jaw. 
 
 
 
 
 
14 
 
 
Database S1. Transcripts enriched in cranial neural crest cells identified by 
comparative RNA-seq analysis of neural crest subpopulations. This dataset has been 
deposited in NCBI's Gene Expression Omnibus under accession number GSE75125. 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75125) 
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